Investing in Cocrystal Pharma, Inc. (COCP)  ➔  Intrinsic value

Prev. close$1.03 
ModelValueUpside
Chepakovich$0.57-45%
Graham-Dodd$0.00-100%
Graham$11.09+977%
Previous Close$1.03  
Valuation MethodValuePotential 
Chepakovich Model$0.57-45%recalculate
Graham-Dodd$0.00-100%recalculate
Graham Formula$11.09+977%recalculate

Latest news

Company description

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.